Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 107

1.

Response: DCIS and Breast Cancer: Challenging the Paradigm (Authors Victoria Sopik and Steven A. Narod)".

Schaapveld M, Wesseling J.

Ann Surg. 2017 Jul 10. doi: 10.1097/SLA.0000000000002418. [Epub ahead of print] No abstract available.

PMID:
28697052
2.

Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.

van Eggermond AM, Schaapveld M, Janus CP, de Boer JP, Krol AD, Zijlstra JM, van der Maazen RW, Kremer LC, van Leerdam ME, Louwman MW, Visser O, De Bruin ML, Aleman BM, van Leeuwen FE.

Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.177. [Epub ahead of print]

PMID:
28632726
3.

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Elshof LE, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J, Schaapveld M.

Ann Surg. 2017 Apr 3. doi: 10.1097/SLA.0000000000002239. [Epub ahead of print]

PMID:
28375855
4.

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, de Munck L, van Leeuwen FE, Wesseling J.

Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.

5.

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BMP.

Blood. 2017 Apr 20;129(16):2257-2265. doi: 10.1182/blood-2016-09-740332. Epub 2017 Jan 31.

6.

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2017 Jan;161(2):389-390. doi: 10.1007/s10549-016-4060-0. No abstract available.

PMID:
27878644
7.

Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.

Liu L, Giusti F, Schaapveld M, Aleman B, Lugtenburg P, Meijnders P, Hutchings M, Lemmens V, Bogaerts J, Visser O.

Br J Haematol. 2017 Jan;176(1):65-75. doi: 10.1111/bjh.14379. Epub 2016 Oct 21.

PMID:
27766636
8.

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2016 Oct;159(3):553-63. doi: 10.1007/s10549-016-3973-y. Epub 2016 Sep 8. Erratum in: Breast Cancer Res Treat. 2016 Nov 23;:.

9.

Reply to D. Vordermark and T. Pelz and R. Mazzola et al.

van Nimwegen FA, Cutter DJ, Schaapveld M, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Aug 20;34(24):2941-2. doi: 10.1200/JCO.2016.67.4358. Epub 2016 May 2. No abstract available.

PMID:
27138579
10.

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72. doi: 10.1016/j.ijrobp.2015.11.040. Epub 2015 Dec 14.

PMID:
27026313
11.

Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study.

Paalman CH, van Leeuwen FE, Aaronson NK, de Boer AG, van de Poll-Franse L, Oldenburg HS, Schaapveld M.

Br J Cancer. 2016 Jan 12;114(1):81-7. doi: 10.1038/bjc.2015.431.

12.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

13.

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.

van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Jan 20;34(3):235-43. doi: 10.1200/JCO.2015.63.4444. Epub 2015 Nov 16.

PMID:
26573075
14.

Cause-specific excess mortality in patients treated for cancer of the oral cavity and oropharynx: A population-based study.

van Monsjou HS, Schaapveld M, Hamming-Vrieze O, de Boer JP, van den Brekel MW, Balm AJ.

Oral Oncol. 2016 Jan;52:37-44. doi: 10.1016/j.oraloncology.2015.10.013. Epub 2015 Nov 6.

PMID:
26553390
15.

Current knowledge and future research directions in treatment-related second primary malignancies.

Morton LM, Swerdlow AJ, Schaapveld M, Ramadan S, Hodgson DC, Radford J, van Leeuwen FE.

EJC Suppl. 2014 Jun;12(1):5-17. doi: 10.1016/j.ejcsup.2014.05.001. Epub 2014 May 29.

16.

The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change?

van Monsjou HS, Schaapveld M, van den Brekel MW, Balm AJ.

Oral Oncol. 2015 Oct;51(10):901-7. doi: 10.1016/j.oraloncology.2015.06.011. Epub 2015 Jul 26.

PMID:
26216340
17.

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE.

JAMA Intern Med. 2015 Jun;175(6):1007-17. doi: 10.1001/jamainternmed.2015.1180.

PMID:
25915855
18.

Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-rays.

van Nimwegen FA, Cutter DJ, Schaapveld M, Rutten A, Kooijman K, Krol AD, Janus CP, Darby SC, van Leeuwen FE, Aleman BM.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):153-60. doi: 10.1016/j.ijrobp.2015.02.019.

PMID:
25863762
19.

Melanoma risk after ovarian stimulation for in vitro fertilization.

Spaan M, van den Belt-Dusebout AW, Schaapveld M, Mooij TM, Burger CW, van Leeuwen FE; OMEGA-project group.

Hum Reprod. 2015 May;30(5):1216-28. doi: 10.1093/humrep/dev023. Epub 2015 Mar 4.

PMID:
25743782
20.

Risk of valvular heart disease after treatment for Hodgkin lymphoma.

Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, Janus CP, van Leeuwen FE, Aleman BM.

J Natl Cancer Inst. 2015 Feb 23;107(4). pii: djv008. doi: 10.1093/jnci/djv008. Print 2015 Apr.

Supplemental Content

Loading ...
Support Center